Vaccination and EU policies: How to strengthen cooperation at EU level? Vaccines Europe perspective

Andrija Visic, Manager – Policy and Government Affairs Vaccines Europe

> FEAM workshop Brussels, 19th November 2018





Vaccines Europe represents

gs

🔁 MSD

UREVA

the RNA people®

GlaxoSmithKline

NOVAVAX Creating Tomorrow's Vaccines T

Vaccines

Ségirus

A CSL Company

12 research-based companies, including SMEs

operating in Europe

80% of Vaccines Europe members' production is in Europe

Worldwide Suppliers

86% is exported outside Europe with 50% of exports going to humanitarian groups (UNICEF, PAHO, GAVI)

Source: The EU Vaccine Industry in Figures, Vaccines Europe http://www.vaccineseurope.eu/about-vaccines/vaccines-europe-in-figures/





Vaccines Europe and the EU initiatives Common Goals for EU Citizen and Public Health

Vaccines industry has a longstanding expertise and experience in the vaccines development and manufacturing with the objective of providing to population safe, effective and innovative vaccines of the highest quality.

⊡ VACCINES PROTECTING AGAINST 26 VACCINE PREVENTABLE DISEASES 26 5 ୢ VACCINATION PREVENTS FIVE PREMATURE DEATHS EVERY MINUTE BETWEEN 1990 AND 2013 DECREASED MORTALITY IN CHILDREN -49% BELOW 5 BY 49% VACCINES SAVE BETWEEN 2 TO 3 MILLION LIVES EVERY YEAR FROM 2-3 🛀 DIPHTHERIA, TETANUS, PERTUSSIS (WHOOPING COUGH), AND MEASLES VACCINES CONTRIBUTE TO THE FIGHT AGAINST ANTIMICROBIAL ₫ 💥 RESISTANCE VACCINES SAVE AND IMPROVE LIVES ACROSS THE ENTIRE LIFE COURSE 0 (NEW BORN, CHILDREN, ADOLESCENTS, PREGNANT WOMEN, ADULTS, OLDER AGE GROUPS) IN THE COMING DECADE, VACCINES ARE PROJECTED TO SAVE 25 25 MILLION MORE PEOPLE

THE VALUE OF VACCINES



Vaccine Research and Development



- Vaccines Europe supports the Commission's intention to • effectiveness and efficiency of EU and national vaccine research and development
- Vaccines Europe conducted a prioritization exercise and selected 7 research ulletareas of the first-ever strategic European roadmap outlining the science and technology investments required for vaccines innovation:



- ✓ Explore emergent in-vitro bioassay technologies and improve in-vitro assay for antibody functional screening
- ✓ Research for selection and analysis of epitopes
- ✓ Support research on structural vaccinology
- \checkmark Create a toolbox of adjuvants with well-defined profile to shape the immune response
- \checkmark Better approach to a combined use of vectors, adjuvants, routes of immunisation
- ✓ Identify innovative design of clinical trials and methodologies to profile volunteers earlier in this trials at an earlier stage
- ✓ Develop expertise and support infrastructures to perform controlled challenges in humans.

Vaccines Europe agrees on launching a multi-stakeholder reflection beyond fundamental research to explore how to overcome barriers to the development of the next generation of vaccines capable of addressing unmet medical needs, including antimicrobial resistance and healthy ageing.



*IPROVE (2016) Innovation Partnership for a Roadmap on Vaccines in Europe which is a collaborative effort involving all relevant stakeholders and funded by DG Research.

increase the



Vaccine Supply and Preparedness

Vaccines are highly technical biological products with complex and lengthy manufacturing, control and release processes.



between 5 and 10 years

are needed to build and license a new facility

Costs up to 600 M for building single manufacturing unit



Up to more than 24 months to produce

Up to 600 manufacturing steps

Up to 680 quality tests (quality control represents 70% of time)

Before the vaccine reaches clinics, doctors and patients





https://www.ifpma.org/resource-centre/the-complex-journey-of-a-vaccine-2/ https://www.vaccineseurope.eu/about-vaccines/vaccines-europe-in-figures/



Thousands of **Employees involved**

Vaccine Supply and Preparedness Industry Proposals*

- **Implementing a mechanism to allow dialogue** between industry and national competent health authorities for vaccination programme implementation would enable industry to anticipate and plan manufacturing accordingly
- Reducing the number of specific national/regional packaging and \bullet labelling requirements to facilitate transfer of vaccines
- Streamlining regulatory requirements in Europe and worldwide \bullet will improve the sustainability of vaccine supply

Vaccines Europe Members are committed to working with stakeholders to ensure a reliable supply of safe, effective and innovative vaccines.




*Vaccines Europe Priorities for Vaccination Policies in Europe, May 2017



Industry position on the different initiatives **Immunisation Information Systems - "IIS"**

- Immunisation Information Systems are the cornerstone of improved ulletvaccination policies in a digital Europe
- IIS could help close the gaps in immunisation coverage at all ages in ulletlife, by facilitating:



Vaccines Europe members could actively **contribute** to information technology and data management, knowledge and expertise



Industry position on the different initiatives Vaccine hesitancy and uptake

- Vaccines Europe sees the actions proposed by the Commission to address the • vaccine hesitancy determinants of confidence, complacency and convenience, including stronger engagement of physicians, nurses and pharmacists, as crucial in view of improving the uptake of effective vaccines and avoid outbreaks of Vaccine Preventable Diseases
- Vaccine Europe considers that member states are in the lead to address these • important issues and should indicate if and how they want industry support.
 - Engage EU and national HCP organisations to increase HCP awareness and education on benefits of vaccination
 - Organize pan EU-vaccination campaigns
 - > Facilitate patient access to vaccination by considering other channels such as pharmacies, etc.
- Vaccines Europe supports an online platform <u>www.VaccinesToday.eu</u>





More info on the Vaccines Europe position can be found at https://www.vaccineseurope.eu/euinitiatives-on-vaccination/





Thank you for your attention!



Website: www.vaccineseurope.eu **Twitter**: https://twitter.com/VaccinesEurope



